Through functional assays in breast and lung cancer, they uncovered that NKILA sensitizes T cells (cytotoxic CD8+ T cells and CD4+ Th1 cells) to activation-induced cell death (AICD), and high expression of NKILA was associated with reduced patient survival (28). This evidence concerns the gene NKILA and lung carcinoma.